AKD Global announced today the discovery of a new class of cancer
treatments in development, providing hope for millions of sufferers. The
spectacular results demonstrate a highly potent effect on cancer cells
with no toxicity to healthy tissue. AKD is raising funds to continue
development.
“The results are
spectacular and with the right support we may be in a position to
rewrite the history books for this disease. We are now working to raise
additional funding to expedite bringing this therapy to market.”
Currently, cancer sufferers who are non-responsive to chemotherapy and
radiation therapy have limited therapeutic options. Treatments are
aggressive and associated with ‘side effects’ which may be as
detrimental as the disease.
“We have discovered and patented a revolutionary new class of
anti-cancer agents that may eliminate the need for these approaches and
change the lives of many cancer patients,” said Dennis Wright, lead
scientist on the project. Early in-vitro data has been successful and
animal testing in mice has shown no adverse effects with oral
administration at concentrations thousands of times higher than used in
our in-vitro testing.